SINOVAC Dispatches First Shipment of 23-valent Pneumococcal Vaccine to Azerbaijan

BEIJING, Apr. 21, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") has dispatched the inaugural shipment of its 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) to Azerbaijan. The vaccines, produced by the Company's subsidiary, Sinovac Biotech Co., Ltd., will support local public health efforts to prevent and control pneumococcal-related diseases.

Pneumococcal bacteria are the most common cause of community-acquired pneumonia. Estimates from the World Health Organization (WHO) indicate that pneumococcal diseases lead to approximately 1.6 million deaths annually, primarily affecting infants and the elderly. In 2008, the WHO categorized pneumococcal disease as a "very high priority" for vaccine prevention.¹

The PPV23 vaccine is SINOVAC's first bacterial vaccine product to receive marketing authorization. Since its launch in 2020, the vaccine has been utilized across numerous provinces in Mainland China and has been authorized for use in the Chinese Hong Kong and Macau Special Administrative Regions.

At the same time, SINOVAC continues to increase the international availability of the vaccine, having previously supplied the product to Côte d'Ivoire. 

This delivery builds on an established period of cooperation between SINOVAC and Azerbaijan's health authorities. During the COVID-19 pandemic, SINOVAC provided a total of 7.75 million vaccine doses to support the country’s national immunization campaign. 

Reference

1. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007--conclusions and recommendations. Wkly Epidemiol Rec. 2008;83(1):1-15.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.